Literature DB >> 7493192

Evaluating the cost-effectiveness of pharmacologic therapy: where we've been and where we're going.

A M Epstein1.   

Abstract

Mesh:

Substances:

Year:  1995        PMID: 7493192

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


× No keyword cloud information.
  1 in total

1.  The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios.

Authors:  Elinor C G Chumney; Andrea K Biddle; Kit N Simpson; Morris Weinberger; Kathryn M Magruder; William N Zelman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.